Reversible lymph node follicular hyperplasia associated with dasatinib treatment of chronic myeloid leukemia in chronic phase.

To the editor: Dasatinib is a tyrosine kinase inhibitor licensed in the treatment of chronic myeloid leukemia (CML) known to exert immunomodulatory effects in vitro and in vivo.[1][1] We report on 9 chronic phase CML patients who developed follicular lymphoid hyperplasia (FLH) apparently caused by